ATCC® Number:VR-2062™
Classification: Poxviridae, Orthopoxvirus
Agent: Vaccinia virus
Strain: vP-60
Original Source: New York State Department of Health strain
Depositors: E Paoletti
Biosafety Level:2
Shipped: frozen
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Host Organism : LLC-MK2 cells (ATCCCCL-7); HeLa cells (ATCCCCL-2); BHK-21(C-13) cells (ATCCCCL-10); chicken embryo fibroblasts
Effect : Yes, in vitro effects: Cytopathic effects in tissue culture
Comments : A recombinant of vaccinia (VTK-79), derivative of ATCC39734, that expresses HSV-1 glycoprotein D. This clone expresses herpes virus type 1 glycoprotein and can be used in the production of antibodies against this protein. [13130] A HindIII-BamHI fragment coding for the herpes virus type 1 glycoprotein (gD) was cloned into VTK-79 (ATCCVR-2031) by in vivo recombination. [13130]
References : 13123: Paoletti E, Panicali D. Modified vaccinia virus. US Patent 4,603,112 dated Jul 29 1986 13130: Paoletti E, Panicali D. Method for immunizing animals with synthetically modified vaccinia virus. US Patent 4,722,848 dated Feb 2 1988 13139: Panicali D, et al. Two major DNA variants present in serially propagated stocks of the WR strain of vaccinia virus. J. Virol. 37: 1000-1010, 1981. PubMed: 6262520 33253: Biberfield. . J. Immunol. Methods 6: 249-259, 1974.